HIV / AIDS in the News

Medicaid: A Lifeline for People Living with HIV - POZ - Health, Life and HIV

 

NMAC Hires Chief Medical Officer To Bridge Public Health Disparities Through Community, Provider, And Policy Education - POZ - Health, Life and HIV

 

Merck's oral HIV treatment non-inferior to Gilead's Biktarvy in late-stage trial - Reuters

 

Merck’s oral HIV treatment meets main goal in late-stage study - The Mighty 790 KFGO

 

As HIV surges, Emory must lead its prevention - The Emory Wheel

 

LGBTQ Agenda: HIV Advocates Blast Delta Air Lines Over PrEP Coverage Hurdles - Lavender Magazine

 

SCOPE: EATG Launches Opportunities to Amplify Community Voices in HIV Prevention - European AIDS Treatment Group

 

Launch of WHO Integrated drug resistance action framework for HIV, hepatitis B and C, and STIs - World Health Organization (WHO)

 

HIV fight at risk as Macron expected to skip major health summit - Euractiv

 

Merck's HIV combo matches Gilead's Biktarvy in latest phase 3 test for islatravir - Fierce Biotech

 

Bus stop’s differing visions; HIV cuts; Weekly gun violence report | Morning Roundup - Billy Penn at WHYY

 

Merck's Investigational Drug in Treatment-Naive Adults with HIV-1 Infection Shows Primary Efficacy - MarketScreener

 

Merck (MRK) Shares Positive Phase 3 Trial Results for HIV Treatm - GuruFocus

 

Merck HIV pill matches Gilead’s Biktarvy in trial (MRK:NYSE) - Seeking Alpha

 

Merck’s two-drug HIV regimen shows non-inferiority in phase 3 trial - Investing.com

 

Merck's oral HIV treatment meets main goal in late-stage study - Yahoo

 

Merck Announces Positive Topline Results from the Pivotal Phase 3 Trial Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) in Treatment-Naïve Adults with HIV-1 Infection - Business Wire

 

Clinical spectrum of Talaromyces marneffei infections in HIV-negative patients: an 18-case series including a rare presentation with gastrointestinal onset, adrenal mass, and hemophagocytic lymphohistiocytosis - BMC Infectious Diseases

 

Biomarkers influence kidney function estimates more so than race among persons with HIV - BioMed Central

 

Cryptococcal Meningitis in an HIV-Negative, Lymphoma Survivor: A Case Report of an Uncommon Dual Pathology - Cureus

 

Integrated drug resistance action framework for HIV, hepatitis B and C and sexually transmitted infections, 2026–2030 - World Health Organization (WHO)

 

Achieving lasting remission for HIV - Knowable Magazine

 

Successful management of severe IRIS associated with disseminated histoplasmosis in an HIV patient using cytokine adsorption therapy and JAK inhibition - BioMed Central

 

Integrating health services for mom and baby could reduce clinic visits by half - spotlightnsp.co.za

 

Scripps Research scientists receive $1.1 million to advance AI modeling for HIV vaccine development - EurekAlert!

 

Trump HIV prevention plan shuts out South Africa — the nation most affected - The Washington Post

 

He relied on USAID for HIV care. Hear his message to Trump - CNN

 

Scripps Research scientists receive $1.1 million to advance AI modeling for HIV vaccine development - European AIDS Treatment Group

 

Integrating HIV/AIDS prevention services into grassroots health helps Việt Nam move closer to end AIDS by 2030 - vietnamnews.vn

 

ECDC report: Testing of HIV, hepatitis B and C in EU/EEA - European AIDS Treatment Group